PREFERENTIAL BINDING OF DAUNOMYCIN TO 5'ATCG AND 5'ATGC SEQUENCES REVEALED BY FOOTPRINTING TITRATION EXPERIMENTS

被引:212
作者
CHAIRES, JB [1 ]
HERRERA, JE [1 ]
WARING, MJ [1 ]
机构
[1] UNIV CAMBRIDGE,SCH MED,DEPT PHARMACOL,CAMBRIDGE CB2 2QD,ENGLAND
关键词
D O I
10.1021/bi00478a006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure are described that identify preferred daunomycin binding sites within the 160 bp tyr T DNA fragment. We have obtained single-bond resolution at 65 of the 160 potential binding sites within the tyr T fragment and have examined the effect of 0–3.0 µM total daunomycin concentration on the susceptibility of these sites toward digestion by DNase I. Four types of behavior are observed: (i) protection from DNase I cleavage; (ii) protection, but only after reaching a critical total daunomycin concentration; (iii) enhanced cleavage; (iv) no effect of added drug. Ten sites were identified as the most strongly protected on the basis of the magnitude of the reduction of their digestion product band areas in the presence of daunomycin. These were identified as the preferred daunomycin binding sites. Seven of these 10 sites are found at the end of the triplet sequences 5′TAGC and 5′TAGC, where the notation TA indicates that either A or T may occupy the position. The remaining three strongly protected sites are found at the ends of the triplet sequence 5′TACTA Of the preferred daunomycin binding sites we identify in this study, the sequence 5′TACG is consistent with the specificity predicted by the theoretical studies of Chen et al. [Chen, K.-X., Gresh, N., & Pullman, B. (1985) J. Biomol. Struct. Dyn. 3, 445–466] and is the very sequence to which daunomycin is observed to be bound in two recent X-ray crystallographic studies. Solution studies, theoretical studies, and crystallographic studies have thus converged to provide a consistent and coherent picture of the sequence preference of this important anticancer antibiotic. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:6145 / 6153
页数:9
相关论文
共 45 条
  • [1] Arcamone F., 1981, DOXORUBICIN ANTICANC
  • [2] BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132
  • [3] BRITT M, 1986, MOL PHARMACOL, V29, P74
  • [4] CHAGAS C, 1987, MOL MECHANISMS CARCI
  • [5] CHAIRES JB, 1986, J BIOL CHEM, V261, P8899
  • [6] DAUNOMYCIN INHIBITS THE B-]Z TRANSITION IN POLY D(G-C)
    CHAIRES, JB
    [J]. NUCLEIC ACIDS RESEARCH, 1983, 11 (23) : 8485 - 8494
  • [7] EQUILIBRIUM STUDIES ON THE INTERACTION OF DAUNOMYCIN WITH DEOXYPOLYNUCLEOTIDES
    CHAIRES, JB
    [J]. BIOCHEMISTRY, 1983, 22 (18) : 4204 - 4211
  • [8] SITE AND SEQUENCE SPECIFICITY OF THE DAUNOMYCIN DNA INTERACTION
    CHAIRES, JB
    FOX, KR
    HERRERA, JE
    BRITT, M
    WARING, MJ
    [J]. BIOCHEMISTRY, 1987, 26 (25) : 8227 - 8236
  • [10] SELF-ASSOCIATION OF DAUNOMYCIN
    CHAIRES, JB
    DATTAGUPTA, N
    CROTHERS, DM
    [J]. BIOCHEMISTRY, 1982, 21 (17) : 3927 - 3932